Open AccessA Genetically Modified Viral Vector for Head and Neck Cancer
Author(s) -
Mouchli Anas,
Han Ziying,
Zheng Jun,
Lajud Shayanne A.,
Sanyal Samudra,
O’Malley Bert W.,
Li Daqing
Publication year - 2012
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599812451426a17
Subject(s) - epidermal growth factor receptor , viral vector , recombinant dna , cancer research , vector (molecular biology) , genetic enhancement , epidermal growth factor , genetically modified organism , virology , biology , transgene , receptor , gene , genetics
Objective 1) To develop a novel genetically modified recombinant adenoviral vector that is expressing epidermal growth factor (EGF) and detargeting from natural coxsackie‐adenoviral receptor (CAR). 2) To apply this novel vector to head and neck cancer (HNC) as an epidermal growth factor receptor (EGFR)‐targeted approach. Method Wild‐type adenoviral fiber knobs were genetically modified with EGF, and a novel adenoviral vector with EGF and EGFR binding properties was constructed. This novel construct was tested in the HNC tumor cells expressing a high level of EGFR. Results The novel genetically modified recombinant adenoviral vector demonstrated EGFR‐targeted properties. The HNC tumor cells expressing high levels of EGFR showed much more viral targeted effects as compared to the cells with low or no EGFR. The nature CAR cell surface entering mechanism was not observed in the HNC tumor cells when the novel was vector applied. Conclusion Our study suggests that the novel genetically modified recombinant adenoviral vector has EGFR‐targeted properties that target the HNC tumor cells, which commonly express high levels of EGFR. This vector has a potential for targeted delivering of diagnostic or therapeutic agents not only for HNC but for any tumor expressing EGFR.